ML 315

• Description:

  ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research[1].

• Product Name Alternative:

  4-Nitrophenylphosphorylcholine; 4-Nitrophenylphosphorylcholine; O-(4-Nitrophenylphosphoryl)choline

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  CDK; DYRK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ml-315.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC(CNC2=NC=NC=C2C3=CC=C4OCOC4=C3)=CC(Cl)=C1

• Molecular Formula:

  C18H13Cl2N3O2

• Molecular Weight:

  374.22

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Coombs TC, et al. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun 15;23 (12) :3654-61.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1440251-53-5]